Clinical trial
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic…
NCT00349596 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00349596 |
|---|---|
| Title | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) |
| Official title | Phase I Study of Low Dose 5-Aza-2'-Deoxycytidine Administered Daily for 5 Days Every Other Week for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Decitabine |
| Enrollment | 40 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2014 |
| Completion | Oct 1, 2014 |
| First posted | Jul 7, 2006 |
| Last update posted | Oct 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: